The EMPA-REG OUTCOME trial, which examined the renoprotective effect of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes [19], compared the empagliflozin-administration (mean eGFR 74.2 mL/min/1.73 m2 (SD 21.6)) and placebo-administration groups (mean eGFR 73.8 mL/min/1.73 m2 (SD 21.1)) in patients with an eGFR of ≥ 30 mL/min/1.73 m2. Here, SLC5A2 is linked to type 2 diabetes mellitus.